Cargando…
A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
BACKGROUND: Secondary hyperparathyroidism may lead to increased cardiovascular risk. The use of cinacalcet may improve bone and cardiovascular health with improved parathormone (PTH) and phosphate control. METHODS: This is an open-label prospective randomised controlled trial to compare progression...
Autores principales: | Eddington, Helen, Chinnadurai, Rajkumar, Alderson, Helen, Ibrahim, Sara T., Chrysochou, Constantina, Green, Darren, Erekosima, Ibi, Hutchison, Alastair, Bubtana, Abdalla, Hegarty, Janet, Kalra, Philip A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989372/ https://www.ncbi.nlm.nih.gov/pubmed/33757437 http://dx.doi.org/10.1186/s12882-021-02312-2 |
Ejemplares similares
-
Safely reducing haemodialysis frequency during the COVID-19 pandemic
por: Lodge, Michelle Da Silva, et al.
Publicado: (2020) -
Myosin heavy chain-9-related disorders (MYH9-RD): a case report
por: Vassallo, Diana, et al.
Publicado: (2013) -
Cinacalcet in HIV haemodialysis patients
por: Belmouaz, Simohamed, et al.
Publicado: (2008) -
Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019) -
Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)